2022
DOI: 10.3390/nu14142790
|View full text |Cite
|
Sign up to set email alerts
|

Arthrospira Enhances Seroclearance in Patients with Chronic Hepatitis B Receiving Nucleos(t)ide Analogue through Modulation of TNF-α/IFN-γ Profile

Abstract: Chronic hepatitis B (CHB) virus infection, causing immune dysfunction and chronic hepatitis, is one of the leading risk factors for hepatocellular cancer. We investigated how Arthrospira affected hepatitis B surface antigen (HBsAg) reduction in CHB patients under continued nucleos(t)ide analogues (NA). Sixty CHB patients who had been receiving NA for at least one year with undetectable HBV DNA were randomized into three groups: control and oral Arthrospira at 3 or 6 g daily add-on therapy groups. Patients were… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
3
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
5
1

Relationship

0
6

Authors

Journals

citations
Cited by 6 publications
(3 citation statements)
references
References 49 publications
0
3
0
Order By: Relevance
“…In clinical trials, some treatments have been evaluated to treat liver diseases by regulating NK cell frequency and function, including lipid-lowing agents (e.g., rosuvastatin) [104], immune regulators (e.g., Toll-like receptor 8 agonist GS-9688) [114,115], antiviral agents (e.g., pegylated interferon-alpha) [116][117][118], anticancer agents (e.g., Sorafenib) [119], mi-croRNAs (e.g., RG-101) [120], and combined therapies (e.g., IL-2 and IFN) [121], as well as organisms (e.g., Arthrospira, a genus of free-floating filamentous cyanobacteria) [122]. In Table 2, we review the functions of different treatments in NK cell regulation.…”
Section: Clinical Evaluationsmentioning
confidence: 99%
See 1 more Smart Citation
“…In clinical trials, some treatments have been evaluated to treat liver diseases by regulating NK cell frequency and function, including lipid-lowing agents (e.g., rosuvastatin) [104], immune regulators (e.g., Toll-like receptor 8 agonist GS-9688) [114,115], antiviral agents (e.g., pegylated interferon-alpha) [116][117][118], anticancer agents (e.g., Sorafenib) [119], mi-croRNAs (e.g., RG-101) [120], and combined therapies (e.g., IL-2 and IFN) [121], as well as organisms (e.g., Arthrospira, a genus of free-floating filamentous cyanobacteria) [122]. In Table 2, we review the functions of different treatments in NK cell regulation.…”
Section: Clinical Evaluationsmentioning
confidence: 99%
“…Treatment with Arthrospira, a genus of free-floating filamentous cyanobacteria, increased serum IFN-γ levels but decreased serum TNF-α and IL-6 and hepatic fibrosis and steatosis in CHB patients receiving NA therapy. [122] Abbreviations: CHB: chronic hepatitis B (CHB); HBeAg: hepatitis B e antigen; HBsAg: hepatitis B surface antigen; IFN: interferon; PBMCs: peripheral blood mononuclear cells; TLR-8: Toll-like receptor 8.…”
Section: Arthrospiramentioning
confidence: 99%
“…Furthermore, oral Arthrospira -diet mice were also used to investigate the possible immunological mechanism of Arthrospira against the hepatitis B virus. The study results showed that Arthrospira treatment can reduce HBsAg and rejuvenate the immune tolerance in CHB patients, by inducing B, T, NK, and macrophage cell activation [ 15 ].…”
mentioning
confidence: 99%